Prasugrel hydrochloride作为一种噻吩吡啶类前体药物，通过拮抗P2Y12受体有效抑制二磷酸腺苷（ADP）诱导的血小板聚集，从而发挥抗血小板功能。
|
英文别名 (English Synonym) |
Prasugrel hydrochloride |
|
中文名称 (Chinese Name) |
盐酸普拉格雷 |
|
靶点 (Target) |
P2Y Receptor |
|
通路 (Pathway) |
GPCR/G protein |
|
CAS号 (CAS NO.) |
389574-19-0 |
|
分子式 (Formula) |
C20H21ClFNO3S |
|
分子量 (Molecular Weight) |
409.9 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007 Jul;5(7):1545-51. doi: 10.1111/j.1538-7836.2007.02598.x. Epub 2007 Apr 19. Erratum in: J Thromb Haemost. 2007 Sep;5(9):1995. PMID: 17456192.
